A2A adenosine receptor deletion is protective in a mouse model of Tauopathy

C. Laurent, S. Burnouf, B. Ferry, V. L. Batalha, J. E. Coelho, Y. Baqi, E. Malik, E. Mariciniak, S. Parrot, A. Van Der Jeugd, E. Faivre, V. Flaten, C. Ledent, R. D'Hooge, N. Sergeant, M. Hamdane, S. Humez, C. E. Müller, L. V. Lopes, L. BuéeD. Blum

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) in humans and mitigates both amyloid and Tau burden in transgenic mouse models. However, the impact of selective A2AR blockade on the progressive development of AD-related lesions and associated memory impairments has not been investigated. In the present study, we removed the gene encoding A2AR from THY-Tau22 mice and analysed the subsequent effects on both pathological (Tau phosphorylation and aggregation, neuro-inflammation) and functional impairments (spatial learning and memory, hippocampal plasticity, neurotransmitter profile). We found that deleting A2ARs protect from Tau pathology-induced deficits in terms of spatial memory and hippocampal long-term depression. These effects were concomitant with a normalization of the hippocampal glutamate/gamma-amino butyric acid ratio, together with a global reduction in neuro-inflammatory markers and a decrease in Tau hyperphosphorylation. Additionally, oral therapy using a specific A2AR antagonist (MSX-3) significantly improved memory and reduced Tau hyperphosphorylation in THY-Tau22 mice. By showing that A2AR genetic or pharmacological blockade improves the pathological phenotype in a Tau transgenic mouse model, the present data highlight A2A receptors as important molecular targets to consider against AD and Tauopathies.

Original languageEnglish
Pages (from-to)97-107
Number of pages11
JournalMolecular Psychiatry
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Tauopathies
Adenosine A2A Receptors
Alzheimer Disease
Transgenic Mice
Adenosine A2 Receptor Antagonists
Butyric Acid
Caffeine
Amyloid
Neurotransmitter Agents
Glutamic Acid
Phosphorylation
Pharmacology
Depression
Pathology
Inflammation
Phenotype
Genes
Spatial Memory
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Laurent, C., Burnouf, S., Ferry, B., Batalha, V. L., Coelho, J. E., Baqi, Y., ... Blum, D. (2016). A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Molecular Psychiatry, 21(1), 97-107. https://doi.org/10.1038/mp.2014.151

A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. / Laurent, C.; Burnouf, S.; Ferry, B.; Batalha, V. L.; Coelho, J. E.; Baqi, Y.; Malik, E.; Mariciniak, E.; Parrot, S.; Van Der Jeugd, A.; Faivre, E.; Flaten, V.; Ledent, C.; D'Hooge, R.; Sergeant, N.; Hamdane, M.; Humez, S.; Müller, C. E.; Lopes, L. V.; Buée, L.; Blum, D.

In: Molecular Psychiatry, Vol. 21, No. 1, 01.01.2016, p. 97-107.

Research output: Contribution to journalArticle

Laurent, C, Burnouf, S, Ferry, B, Batalha, VL, Coelho, JE, Baqi, Y, Malik, E, Mariciniak, E, Parrot, S, Van Der Jeugd, A, Faivre, E, Flaten, V, Ledent, C, D'Hooge, R, Sergeant, N, Hamdane, M, Humez, S, Müller, CE, Lopes, LV, Buée, L & Blum, D 2016, 'A2A adenosine receptor deletion is protective in a mouse model of Tauopathy', Molecular Psychiatry, vol. 21, no. 1, pp. 97-107. https://doi.org/10.1038/mp.2014.151
Laurent, C. ; Burnouf, S. ; Ferry, B. ; Batalha, V. L. ; Coelho, J. E. ; Baqi, Y. ; Malik, E. ; Mariciniak, E. ; Parrot, S. ; Van Der Jeugd, A. ; Faivre, E. ; Flaten, V. ; Ledent, C. ; D'Hooge, R. ; Sergeant, N. ; Hamdane, M. ; Humez, S. ; Müller, C. E. ; Lopes, L. V. ; Buée, L. ; Blum, D. / A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. In: Molecular Psychiatry. 2016 ; Vol. 21, No. 1. pp. 97-107.
@article{4c58455ac50c44a09031fded852f30aa,
title = "A2A adenosine receptor deletion is protective in a mouse model of Tauopathy",
abstract = "Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) in humans and mitigates both amyloid and Tau burden in transgenic mouse models. However, the impact of selective A2AR blockade on the progressive development of AD-related lesions and associated memory impairments has not been investigated. In the present study, we removed the gene encoding A2AR from THY-Tau22 mice and analysed the subsequent effects on both pathological (Tau phosphorylation and aggregation, neuro-inflammation) and functional impairments (spatial learning and memory, hippocampal plasticity, neurotransmitter profile). We found that deleting A2ARs protect from Tau pathology-induced deficits in terms of spatial memory and hippocampal long-term depression. These effects were concomitant with a normalization of the hippocampal glutamate/gamma-amino butyric acid ratio, together with a global reduction in neuro-inflammatory markers and a decrease in Tau hyperphosphorylation. Additionally, oral therapy using a specific A2AR antagonist (MSX-3) significantly improved memory and reduced Tau hyperphosphorylation in THY-Tau22 mice. By showing that A2AR genetic or pharmacological blockade improves the pathological phenotype in a Tau transgenic mouse model, the present data highlight A2A receptors as important molecular targets to consider against AD and Tauopathies.",
author = "C. Laurent and S. Burnouf and B. Ferry and Batalha, {V. L.} and Coelho, {J. E.} and Y. Baqi and E. Malik and E. Mariciniak and S. Parrot and {Van Der Jeugd}, A. and E. Faivre and V. Flaten and C. Ledent and R. D'Hooge and N. Sergeant and M. Hamdane and S. Humez and M{\"u}ller, {C. E.} and Lopes, {L. V.} and L. Bu{\'e}e and D. Blum",
year = "2016",
month = "1",
day = "1",
doi = "10.1038/mp.2014.151",
language = "English",
volume = "21",
pages = "97--107",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A2A adenosine receptor deletion is protective in a mouse model of Tauopathy

AU - Laurent, C.

AU - Burnouf, S.

AU - Ferry, B.

AU - Batalha, V. L.

AU - Coelho, J. E.

AU - Baqi, Y.

AU - Malik, E.

AU - Mariciniak, E.

AU - Parrot, S.

AU - Van Der Jeugd, A.

AU - Faivre, E.

AU - Flaten, V.

AU - Ledent, C.

AU - D'Hooge, R.

AU - Sergeant, N.

AU - Hamdane, M.

AU - Humez, S.

AU - Müller, C. E.

AU - Lopes, L. V.

AU - Buée, L.

AU - Blum, D.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) in humans and mitigates both amyloid and Tau burden in transgenic mouse models. However, the impact of selective A2AR blockade on the progressive development of AD-related lesions and associated memory impairments has not been investigated. In the present study, we removed the gene encoding A2AR from THY-Tau22 mice and analysed the subsequent effects on both pathological (Tau phosphorylation and aggregation, neuro-inflammation) and functional impairments (spatial learning and memory, hippocampal plasticity, neurotransmitter profile). We found that deleting A2ARs protect from Tau pathology-induced deficits in terms of spatial memory and hippocampal long-term depression. These effects were concomitant with a normalization of the hippocampal glutamate/gamma-amino butyric acid ratio, together with a global reduction in neuro-inflammatory markers and a decrease in Tau hyperphosphorylation. Additionally, oral therapy using a specific A2AR antagonist (MSX-3) significantly improved memory and reduced Tau hyperphosphorylation in THY-Tau22 mice. By showing that A2AR genetic or pharmacological blockade improves the pathological phenotype in a Tau transgenic mouse model, the present data highlight A2A receptors as important molecular targets to consider against AD and Tauopathies.

AB - Consumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) in humans and mitigates both amyloid and Tau burden in transgenic mouse models. However, the impact of selective A2AR blockade on the progressive development of AD-related lesions and associated memory impairments has not been investigated. In the present study, we removed the gene encoding A2AR from THY-Tau22 mice and analysed the subsequent effects on both pathological (Tau phosphorylation and aggregation, neuro-inflammation) and functional impairments (spatial learning and memory, hippocampal plasticity, neurotransmitter profile). We found that deleting A2ARs protect from Tau pathology-induced deficits in terms of spatial memory and hippocampal long-term depression. These effects were concomitant with a normalization of the hippocampal glutamate/gamma-amino butyric acid ratio, together with a global reduction in neuro-inflammatory markers and a decrease in Tau hyperphosphorylation. Additionally, oral therapy using a specific A2AR antagonist (MSX-3) significantly improved memory and reduced Tau hyperphosphorylation in THY-Tau22 mice. By showing that A2AR genetic or pharmacological blockade improves the pathological phenotype in a Tau transgenic mouse model, the present data highlight A2A receptors as important molecular targets to consider against AD and Tauopathies.

UR - http://www.scopus.com/inward/record.url?scp=84951905228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951905228&partnerID=8YFLogxK

U2 - 10.1038/mp.2014.151

DO - 10.1038/mp.2014.151

M3 - Article

C2 - 25450226

AN - SCOPUS:84951905228

VL - 21

SP - 97

EP - 107

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 1

ER -